← All market reports

United States Healthcare Market Research Reports 2026

Regulatory focus: FDA

The US pharmaceutical market at USD 615 billion represents approximately 45% of global pharmaceutical revenues—making US launch the primary commercial value driver for most innovators. IRA drug negotiation, biosimilar competition growth (Humira LOE, insulin biosimilar market), and GLP-1 market explosion (Ozempic, Wegovy, Mounjaro) are the three macro forces reshaping US commercial strategy through 2030. BioNixus provides comparative US-GCC intelligence for multinational commercial teams managing cross-regional pricing architectures.

For cross-country benchmarking, use the market reports hub and compare therapy-specific dynamics through the oncology therapy hub.